William J. Sandborn
Experienced in Campylobacter Infection

Dr. William J. Sandborn

Gastroenterology
200 W Arbor Dr, 
San Diego, CA 
Experienced in Campylobacter Infection
200 W Arbor Dr, 
San Diego, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

William Sandborn is a Gastroenterologist in San Diego, California. Dr. Sandborn is rated as an Experienced provider by MediFind in the treatment of Campylobacter Infection. His top areas of expertise are Crohn's Disease, Hemorrhagic Proctocolitis, Ulcerative Colitis, Endoscopy, and Colonoscopy.

His clinical research consists of co-authoring 600 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Campylobacter Infection.

Specialties
Gastroenterology
Licenses
Internal Medicine in CA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

200 W Arbor Dr, San Diego, CA 92103

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
Enrollment Status: Completed
Publish Date: October 14, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
Enrollment Status: Active_not_recruiting
Publish Date: October 10, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
Enrollment Status: Completed
Publish Date: May 31, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
Pharmacokinetics of Infliximab and Tumor Necrosis Factor Concentrations in Serum, Stool, and Colonic Mucosa in Acute Severe Ulcerative Colitis
Pharmacokinetics of Infliximab and Tumor Necrosis Factor Concentrations in Serum, Stool, and Colonic Mucosa in Acute Severe Ulcerative Colitis
Enrollment Status: Active_not_recruiting
Publish Date: May 16, 2025
Intervention Type: Drug
A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
Enrollment Status: Completed
Publish Date: June 21, 2024
Intervention Type: Drug
Study Drug: Ontamalimab
Study Phase: Phase 3
An Adaptive Phase 2, Randomized, Double Blind, Placebo Controlled Study of LY3471851 (NKTR 358) in Patients With Moderately to Severely Active Ulcerative Colitis
An Adaptive Phase 2, Randomized, Double Blind, Placebo Controlled Study of LY3471851 (NKTR 358) in Patients With Moderately to Severely Active Ulcerative Colitis
Enrollment Status: Terminated
Publish Date: September 05, 2023
Intervention Type: Drug
Study Drug: LY3471851
Study Phase: Phase 2
A Multicentre Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Safety, Tolerability, Efficacy, Dose-response, Pharmacokinetics and Pharmacodynamics of Repeat Dosing of an Anti-LAG3 Cell Depleting Monoclonal Antibody (GSK2831781) in Patients With Active Ulcerative Colitis
A Multicentre Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Safety, Tolerability, Efficacy, Dose-response, Pharmacokinetics and Pharmacodynamics of Repeat Dosing of an Anti-LAG3 Cell Depleting Monoclonal Antibody (GSK2831781) in Patients With Active Ulcerative Colitis
Enrollment Status: Terminated
Publish Date: April 27, 2022
Intervention Type: Drug
Study Drug: GSK2831781
Study Phase: Phase 2
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)
Enrollment Status: Completed
Publish Date: January 14, 2022
Intervention Type: Other, Drug
Study Phase: Phase 3
PhaRmacOkinetics and PHarmacodynamic BiomarkErs of Janus Kinase Inhibitor Therapy in PatIents With Ulcerative Colitis (PROPHETIC)
PhaRmacOkinetics and PHarmacodynamic BiomarkErs of Janus Kinase Inhibitor Therapy in PatIents With Ulcerative Colitis (PROPHETIC)
Enrollment Status: Terminated
Publish Date: January 04, 2022
Intervention Type: Drug
A Phase III, Randomized Multi-centre, Double-blind, Parallel Group, Active Comparator Study to Compare the Efficacy and Safety of SPD476 (Mesalazine)2.4g/Day Once Daily With Asacol 1.6g/Day Twice Daily in the Maintenance of Remission in Patients With Ulcerative Colitis
A Phase III, Randomized Multi-centre, Double-blind, Parallel Group, Active Comparator Study to Compare the Efficacy and Safety of SPD476 (Mesalazine)2.4g/Day Once Daily With Asacol 1.6g/Day Twice Daily in the Maintenance of Remission in Patients With Ulcerative Colitis
Enrollment Status: Completed
Publish Date: June 14, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 302)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 302)
Enrollment Status: Terminated
Publish Date: April 26, 2021
Intervention Type: Drug
Study Phase: Phase 3
View 10 Less Clinical Trials

600 Total Publications

Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn's disease and ulcerative colitis: 2-year results from open-label extensions of two randomized controlled trials (LIBERTY).
Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn's disease and ulcerative colitis: 2-year results from open-label extensions of two randomized controlled trials (LIBERTY).
Journal: Journal of Crohn's & colitis
Published: April 17, 2025
Similar Doctors
Advanced in Campylobacter Infection
Dr. Erick Alayo
Gastroenterology
Advanced in Campylobacter Infection
Dr. Erick Alayo
Gastroenterology
587 3rd Ave, 
Chula Vista, CA 
 (10.0 miles away)
619-382-3315
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Erick Alayo is a Gastroenterologist in Chula Vista, California. Dr. Alayo is rated as a Distinguished provider by MediFind in the treatment of Campylobacter Infection. His top areas of expertise are Menetrier Disease, Chronic Erosive Gastritis, Non-Alcoholic Fatty Liver Disease, and Gastroesophageal Reflux Disease (GERD).

Advanced in Campylobacter Infection
Dr. Robert Goldklang
Gastroenterology
Advanced in Campylobacter Infection
Dr. Robert Goldklang
Gastroenterology

Genesis Healthcare Partners PC

700 Garden View Ct, Suite 102, 
Encinitas, CA 
 (21.8 miles away)
760-783-0441
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Robert Goldklang is a Gastroenterologist in Encinitas, California. Dr. Goldklang is rated as a Distinguished provider by MediFind in the treatment of Campylobacter Infection. His top areas of expertise are Indigestion, Diverticular Disease, Irritable Bowel Syndrome (IBS), Endoscopy, and Colonoscopy.

Advanced in Campylobacter Infection
Dr. Naveen Gara
Gastroenterology
Advanced in Campylobacter Infection
Dr. Naveen Gara
Gastroenterology

Gastroenterology And Liver Institute PC

935 E Pennsylvania Ave, 
Escondido, CA 
 (26.4 miles away)
760-690-2800
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Naveen Gara is a Gastroenterologist in Escondido, California. Dr. Gara is rated as an Advanced provider by MediFind in the treatment of Campylobacter Infection. His top areas of expertise are Nonalcoholic Steatohepatitis (NASH), Hepatitis, Portal Hypertension, Endoscopy, and Colonoscopy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Sandborn's expertise for a condition
ConditionClose
View All 7 Elite Conditions
View All 7 Advanced Conditions
View All 22 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile